Medisse raises $3.5M for new med device biomaterial

Medisse in The Netherlands attracted $3.5 million in new Series B equity funding, money that will come in handy as the company develops its FlexiSurge adhesion barrier. Medisse, first launched in 2009, develops resorbable soft tissue-related implants that are based on a flexible material. Plans call for using the funds to launch a proof of concept clinical trial for FlexiSurge, with a goal of obtaining a CE mark. The latest investment round drew one new investor--IIG--along with previous investors BioGeneration Ventures and Omnes Capital. As part of the deal, the Dutch Ministry of Economic Affairs also issued an innovation credit, the company notes. Item